Association between mood stabilizers and hypothyroidism in patients with bipolar disorders: A nested, matched case-control study

Bipolar Disorders

Volumn 12, Issue 3, 2010, Pages 253-263

  Gau, Churn Shiouh ^a,b   Chang, Ching Jui ^c,d,e   Tsai, Fang Ju ^f   Chao, Pei Fong ^a   Gau, Susan Shur Fen ^c,g  

^a Graduate Institute of Clinical Medicine   (Taiwan)

^b School of Pharmacy   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d CATHAY GENERAL HOSPITAL   (Taiwan)

^e FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^f EN CHU KONG HOSPITAL   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bipolar disorders; Carbamazepine; Hypothyroidism; Lithium; Valproate

Indexed keywords

AMIODARONE; ANTIDEPRESSANT AGENT; ANTITHYROID AGENT; CARBAMAZEPINE; LITHIUM; MOOD STABILIZER; PHENYTOIN; VALPROIC ACID; TRANQUILIZER;

ADULT; AGE; ARTICLE; BIPOLAR DISORDER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA BASE; DRUG USE; EPILEPSY; FEMALE; HUMAN; HYPOTHYROIDISM; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TAIWAN; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLASSIFICATION; DRUG COMBINATION; MIDDLE AGED; PUBLIC HEALTH; RISK; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; ODDS RATIO; RISK FACTORS; TAIWAN;

EID: 77953933214     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2010.00814.x     Document Type: Article

References (57)

1. Merikangas KR, Akiskal HS, Angst J. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007, 64:543-552.
2. Mitchell PB, Slade T, Andrews G. Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey. Psychol Med 2004, 34:777-785.
3. Perala J, Suvisaari J, Saarni SI. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007, 64:19-28.
4. Oswald P, Souery D, Kasper S. Current issues in bipolar disorder: a critical review. Eur Neuropsychopharmacol 2007, 17:687-695.
5. Azorin JM, Findling RL. Valproate use in children and adolescents with bipolar disorder. CNS Drugs 2007, 21:1019-1033.
6. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002, 159:1-50.
7. Goodwin GM, Young AH. The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: a summary. J Psychopharmacol 2003, 17:3-6.
8. Yatham LN, Kennedy SH, O'Donovan C. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006, 8:721-739.
9. Calabrese JR, Kasper S, Johnson G. International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry 2004, 65:571-579.
10. Suppes T, Dennehy EB, Hirschfeld RM. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005, 66:870-886.
11. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007, 9:394-412.
12. Roberts CG, Ladenson PW. Hypothyroidism. Lancet 2004, 363:793-803.
13. Flynn RWV, MacDonald TM, Morris AD, Jung RT, Leese GP. The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population. J Clin Endocrinol Metab 2004, 89:3879-3884.
14. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid 2007, 17:1211-1223.
15. Laurberg P, Bulow Pedersen I, Pedersen KM, Vestergaard H. Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake. Thyroid 1999, 9:33-38.
16. Pedersen BK, Steensberg A. Exercise and hypoxia: effects on leukocytes and interleukin-6-shared mechanisms? Med Sci Sports Exerc 2002, 34:2004-2013.
17. Carle A, Laurberg P, Pedersen IB. Epidemiology of subtypes of hypothyroidism in Denmark. Eur J Endocrinol 2006, 154:21-28.
18. Leese GP, Flynn RV, Jung RT, Macdonald TM, Murphy MJ, Morris AD. Increasing prevalence and incidence of thyroid disease in Tayside, Scotland: the Thyroid Epidemiology Audit and Research Study (TEARS). Clin Endocrinol 2008, 68:311-316.
19. Teng W, Shan Z, Teng X. Effect of iodine intake on thyroid diseases in China. N Engl J Med 2006, 354:2783-2793.
20. Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999, 60:249-255.
21. Bocchetta A, Mossa P, Velluzzi F, Mariotti S, Zompo MD, Loviselli A. Ten-year follow-up of thyroid function in lithium patients. J Clin Psychopharmacol 2001, 21:594-598.
22. Zhang ZJ, Qiang L, Kang WH. Differences in hypothyroidism between lithium-free and -treated patients with bipolar disorders. Life Sci 2006, 78:771-776.
23. Henry C. Lithium side-effects and predictors of hypothyroidism in patients with bipolar disorder: sex differences. J Psychiatry Neurosci 2002, 27:104-107.
24. Ahmadi-Abhari SA, Ghaeli P, Fahimi F. Risk factors of thyroid abnormalities in bipolar patients receiving lithium: a case control study. BMC Psychiatry 2003, 3:4.
25. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. J Affect Disord 2005, 87:313-317.
26. Chiang M, Gau SS. Validation of attention-deficit-hyperactivity disorder subtypes among Taiwanese children using neuropsychological functioning. Aust N Z J Psychiatry 2008, 42:526-535.
27. Valle J, Ayuso-Gutierrez JL, Abril A, Ayuso-Mateos JL. Evaluation of thyroid function in lithium-naive bipolar patients. Eur Psychiatry 1999, 14:341-345.
28. Post RM, Kramlinger KG, Joffe RT. Rapid cycling bipolar affective disorder: lack of relation to hypothyroidism. Psychiatry Res 1997, 72:1-7.
29. Urabe M, Hershman JM, Pang XP, Murakami S, Sugawara M. Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology 1991, 129:807-814.
30. Bhattacharyya B, Wolff J. Stabilization of microtubules by lithium ion. Biochem Biophys Res Commun 1976, 73:383-390.
31. Bagchi N, Brown TR, Mack RE. Studies on the mechanism of inhibition of thyroid function by lithium. Biochim Biophys Acta 1978, 542:163-169.
32. Vainionpaa LK, Mikkonen K, Rattya J. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004, 45:197-203.
33. Caksen H, Dulger H, Cesur Y, Atas B, Tuncer O, Odabas D. Evaluation of thyroid and parathyroid functions in children receiving long-term carbamazepine therapy. Int J Neurosci 2003, 113:1213-1217.
34. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol 2001, 25:43-46.
35. Isojarvi JI, Pakarinen AJ, Myllyla VV. Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol 1989, 46:1175-1178.
36. Isojarvi JI, Turkka J, Pakarinen AJ, Kotila M, Rattya J, Myllyla VV. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia 2001, 42:930-934.
37. Eiris-Punal J, Del Rio-Garma M, Del Rio-Garma MC, Lojo-Rocamonde S, Novo-Rodriguez I, Castro-Gago M. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 1999, 40:1761-1766.
38. Mikati MA, Tarabay H, Khalil A, Rahi AC, El Banna D, Najjar S. Risk factors for development of subclinical hypothyroidism during valproic acid therapy. J Pediatr 2007, 151:178-181.
39. Gau SS, Chung CH, Gau CS. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. J Clin Psychopharmacol 2008, 28:271-278.
40. Gau SS, Chao PF, Lin YJ, Chang CJ, Gau CS. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study. J Clin Psychopharmacol 2008, 28:509-517.
41. Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemol Ment Health 2006, 2:23.
42. Cansu A, Serdaroglu A, Camurdan O, Hirfanoglu T, Bideci A, Gucuyener K. The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia 2006, 47:1855-1859.
43. de Vries L, Karasik A, Landau Z, Phillip M, Kiviti S, Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia 2007, 48:470-477.
44. Caksen H, Dülger H, Cesur Y, Odabaş D, Tuncer O, Ataş B. No effect of long-term valproate therapy on thyroid and parathyroid functions in children. Int J Neurosci 2002, 112:1371-1374.
45. Lee S, Chow CC, Wing YK, Shek CC. Thyroid abnormalities during chronic lithium treatment in Hong Kong Chinese: a controlled study. J Affect Disord 1992, 26:173-178.
46. Post RM, Leverich GS, Altshuler LL. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord 2003, 5:310-319.
47. Gracious BL, Findling RL, Seman C, Youngstrom EA, Demeter CA, Calabrese JR. Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex sodium. J Am Acad Child Adolesc Psychiatry 2004, 43:215-220.
48. Shulman KL, Sykora K, Gill SS. New thyroxine treatment in older adults beginning lithium therapy - Implications for clinical practice. Am J Geriatr Psychiatry 2005, 13:299-304.
49. Miller FR, Paulson D, Prihoda TJ, Otto RA. Risk factors for the development of hypothyroidism after hemithyroidectomy. Arch Otolaryngol Head Neck Surg 2006, 132:36-38.
50. Dunner DL. Drug interactions of lithium and other antimanic/mood-stabilizing medications. J Clin Psychiatry 2003, 64(Suppl. 5):38-43.
51. Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H. Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J Surg Res 2010, 159:640-644.
52. Gitlin MJ. Lithium-induced renal insufficiency. J Clin Psychopharmacol 1993, 13:276-279.
53. Markowitz G, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D'Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000, 11:1439-1448.
54. Koenig SA, Buesing D, Longin E. Valproic acid-induced hepatopathy: nine new fatalities in Germany from 1994 to 2003. Epilepsia 2006, 47:2027-2031.
55. McLaren KD, Marangell LB. Special considerations in the treatment of patients with bipolar disorder and medical co-morbidities. Ann Gen Hosp Psychiatry 2004, 3:7.
56. Salpekar JA, Conry JA, Doss W. Clinical experience with anticonvulsant medication in pediatric epilepsy and comorbid bipolar spectrum disorder. Epilepsy Behav 2006, 9:327-334.
57. Lo JC, Chertow GM, Go AS, Hsu C-Y. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int 2005, 67:1047-1052.